Physician profile
Seema Basi
NPI 1497793202
$1,448.45
in general payments reported to CMS, 2019-2025
19 companies · $145 in 2025
The $145 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $170 · 2020: $211 · 2021: $13.81 · 2022: $231 · 2023: $264 · 2024: $414 · 2025: $145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $784 · Education: $39.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $783.99 |
| Education | $39.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $383.17 | 2019-2025 | Velphoro, Korsuva, Velphoro |
| Otsuka America Pharmaceutical, INC. | $235.80 | 2019-2025 | Jynarque, Voyxact |
| Amgen INC. | $173.63 | 2019-2025 | Tavneos, Krystexxa |
| Astrazeneca Pharmaceuticals LP | $115.94 | 2019-2024 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $89.55 | 2022-2024 | |
| Akebia Therapeutics INC | $62.80 | 2020-2022 | |
| Glaxosmithkline, LLC. | $53.70 | 2023-2024 | Jesduvroq, Benlysta |
| Aurinia Pharma U.S., INC. | $48.45 | 2023-2024 | Lupkynis |
| Vifor Pharma, INC. | $48.18 | 2019-2024 | Veltassa |
| Ardelyx, INC. | $38.03 | 2024-2025 | Ibsrela |
| Novo Nordisk INC | $37.45 | 2024 | Rivfloza |
| Novartis Pharmaceuticals Corporation | $34.58 | 2024 | |
| Travere Therapeutics, INC. | $29.41 | 2023 | |
| Fresenius USA Manufacturing, INC. | $19.03 | 2023 | Velphoro, Korsuva |
| Baxter Healthcare | $18.72 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $16.66 | 2023 | Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.37 | 2024 | Jardiance |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $14.24 | 2024 | |
| Mallinckrodt Hospital Products INC. | $13.74 | 2024 | Terlivaz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seema Basi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.